Incretin Atlas › Molecules › Efinopegdutide
Efinopegdutide
GLP-1/GCG · s.c. · MSD (Hanmi)
Summary
- Also known as
- MK-6024
- Mechanism
- GLP-1/GCG
- Route
- s.c.
- Company
- MSD (Hanmi)
- Highest development stage
- phase 2
- Status (as of data cut)
- Phase 2b MASH verify
- Next milestone
- Phase 3 MASH
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 0 no data | ||
| T2D | 0 no data | ||
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 1 phase 2 / signal | Positive phase 2b (Lancet, Nov 2026) | Phase 2b, Lancet 2026 |
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Outcome trials
Other indications
Phase 2b Efinopegdutide · MASH F2–F3 · 52 weeks · n = 386 abstract
MASH resolution without worsening of fibrosis +43.0 / +49.5 / +47.8 percentage points vs placebo (4 / 7 / 10 mg); fibrosis improvement +21.7 / +30.4 / +13.0 (10 mg not significant). Open-label semaglutide 2.4 mg arm: 53 % and 25 %.
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| MASH resolution without worsening of fibrosis 4 mg week 52 | +56.0 | +13.0 | +43.0 (+25.7 to +57.8) percentage points | abstract |
| MASH resolution without worsening of fibrosis 7 mg week 52 | +63.0 | +13.0 | +49.5 (+31.4 to +64.2) percentage points | abstract |
| MASH resolution without worsening of fibrosis 10 mg week 52 | +61.0 | +13.0 | +47.8 (+30.7 to +62.0) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 4 mg week 52 | +43.0 | +21.0 | +21.7 (+7.1 to +35.7) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 7 mg week 52 | +52.0 | +21.0 | +30.4 (+15.4 to +44.3) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 10 mg week 52 | +34.0 | +21.0 | +13.0 (−1.2 to +26.8) percentage points | abstract |
Verbatim quotes (6)
- MASH resolution without worsening of fibrosis
difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
- MASH resolution without worsening of fibrosis
difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
- MASH resolution without worsening of fibrosis
difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
- Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
- Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
- Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
Registered trials (4)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| MK-6024-017 A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | MASH | Phase 2 | completed | 2024-07 → 2026-08 | 85 | Completed; results not in the atlas yet | NCT06465186 |
| MK-6024-016 Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) | MASH | Phase 2 | completed | 2024-07 → 2025-06 | 124 | Completed; results not in the atlas yet | NCT06482112 |
| Phase 2b A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | CV outcomes | Phase 2 | completed | 2023-06 → 2025-12 | 381 | Completed; results not yet public | NCT05877547 |
| MK-6024-001 A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | MASH | Phase 2 | completed | 2021-08 → 2022-10 | 145 | Completed; results not in the atlas yet | NCT04944992 |
Primary sources
- Lawitz E, Wong VW, Shankar RR, Francque S, Patel K, Miele L, et al. Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study. Lancet. 2026. PMID: 43003105.
- Merck Sharp & Dohme LLC. A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis. ClinicalTrials.gov identifier NCT05877547. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05877547
How to cite this page
Medical Adviser's Group. Incretin Atlas: Efinopegdutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/efinopegdutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.